NEW
YORK, Feb. 22, 2023 /PRNewswire/ -- AnPac
Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we")
(ANPC), a company with operations in the
United States and China
focused on early cancer screening and detection and plans to enter
into the operation of a business-to-business e-commerce food
platform focused on the sale of Asian sourced food products,
announced up-dated positive results from its first major multi-year
and multi-cancer test follow-up study. To date, the study has
enrolled over 18,000 individuals from a general population of
230,000 persons located in China. The test subjects were
tested using AnPac Bio's Cancer Differentiation Analysis (CDA)
method. We believe that the study is one of the largest
multi-year and multi-cancer follow-up studies in the world. The
multi-year study fully validated that CDA method is a multi-cancer
detection method which is capable of detecting multiple cancer
types with statistical significance. We believe that the CDA
method may become a cost effective, multi-cancer screening
method.
As announced previously, the study has enrolled individuals who
were first tested using the CDA method. Based on the CDA test
results, individuals were classified into high risk, medium risk
and low risk groups, and individuals from all three groups were
enrolled in the study. In the study, medium cancer risk group
accounted for the greater number of enrolled individuals while high
cancer risk group has the fewest number of enrolled
individuals. During the study, the enrolled individuals were
contacted regularly and their health status were
recorded.
Health institutions including hospitals have reported that 2,837
individuals within the study were identified as cancer, pre-cancer
and disease patients. The confirmed cancer cases contained 22
types of cancer, with the top five confirmed cancer types being
colorectal cancer, lung cancer, stomach cancer, prostatic cancer
and breast cancer. The study also identified patients with
esophageal cancer which does not have a bio-marker. The confirmed
cases also include 27 types of pre-cancer. Statistical
analysis showed that there is also a strong correlation between CDA
test score and cancer occurrence, with the higher the CDA value,
the higher the cancer risk. If the enrolled individuals are
normalized to the sample size in which all three enrolled groups
have the same amount of individuals, the confirmed cancer cases
would be distributed as: 91.7% in the high risk group, 7.5% in the
medium cancer risk group, and only 0.8% in the low risk
group. The above data on confirmed cancer case distribution
as a function of CDA score based cancer risk ranking (high cancer
risk, medium cancer risk and low cancer risk) indicate that CDA
technology is effective in finding and predicting the cancer
occurrence.
About AnPac Bio
AnPac Bio-Medical Science Co., Ltd. is a biotechnology company
focused on early cancer screening and detection, with 155 issued
patents as of June 30, 2022. With two
certified clinical laboratories in China and one CLIA and CAP accredited clinical
laboratory in the United States,
AnPac Bio performs a suite of cancer screening and detection tests,
including CDA (Cancer Differentiation Analysis), bio-chemical,
immunological, and genomics tests. The Company intends to enter the
business-to-business e-commerce food business with the formation of
its wholly-owned subsidiary Fresh2 Technology Inc and the
acquisition of Fresh2 Ecommerce Inc.
For more information, please
visit: https://www.Anpacbio.com.
For investor and media inquiries, please
contact:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-917-609-0333 (US)
Email: tina.xiao@ascent-ir.com
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements are made under the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995 and are relating
to the Company's future financial and operating performance. The
Company has attempted to identify forward-looking statements by
terminologies including "believes," "estimates," "anticipates,"
"expects," "plans," "projects," "intends," "potential," "target,"
"aim," "predict," "outlook," "seek," "goal" "objective," "assume,"
"contemplate," "continue," "positioned," "forecast," "likely,"
"may," "could," "might," "will," "should," "approximately" or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
based on current expectations, assumptions and uncertainties
involving judgments about, among other things, future economic,
competitive and market conditions and future business decisions,
all of which are difficult or impossible to predict accurately and
many of which are beyond the Company's control. These statements
also involve known and unknown risks, uncertainties and other
factors that may cause the Company's actual results to be
materially different from those expressed or implied by any
forward-looking statement. Known and unknown risks, uncertainties
and other factors include, but are not limited to, our ability to
comply with Nasdaq Listing Rules, the implementation of our
business model and growth strategies; trends and competition in the
cancer screening and detection market; our expectations regarding
demand for and market acceptance of our cancer screening and
detection tests and our ability to expand our customer base; our
ability to obtain and maintain intellectual property protections
for our CDA technology and our continued research and development
to keep pace with technology developments; our ability to obtain
and maintain regulatory approvals from the NMPA, the FDA and the
relevant U.S. states and have our laboratories certified or
accredited by authorities including the CLIA; our future business
development, financial condition and results of operations and our
ability to obtain financing cost-effectively; potential changes of
government regulations; general economic and business conditions in
China and elsewhere; our ability
to hire and maintain key personnel; our relationship with our major
business partners and customers; and the duration of the
coronavirus outbreaks and their potential adverse impact on the
economic conditions and financial markets and our business and
financial performance, such as resulting from reduced commercial
activities due to quarantines and travel restrictions instituted by
China, the U.S. and many other
countries around the world to contain the spread of the virus.
Additionally, all forward-looking statements are subject to the
"Risk Factors" detailed from time to time in the Company's most
recent Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission. Because of these and other
risks, uncertainties and assumptions, undue reliance should not be
placed on these forward-looking statements. In addition, these
statements speak only as of the date of this press release and,
except as may be required by law, the Company undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
View original
content:https://www.prnewswire.com/news-releases/anpac-bio-announces-positive-results-from-its-multi-year-and-multi-cancer-test-follow-up-study-301753018.html
SOURCE ANPAC BIO-MEDICAL SCIENCE CO., LTD